These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
59 related articles for article (PubMed ID: 13483762)
1. [Effects of vasolastine in dementia arteriosclerotica]. BUIS C; HUTTER D Ned Tijdschr Geneeskd; 1957 Sep; 101(37):1690-4. PubMed ID: 13483762 [No Abstract] [Full Text] [Related]
2. [Effects of vasolastine on experimental sclerosis in rats and in dogs and patients with arteriosclerotic symptoms]. HOOGERWERF S Geneeskd Gids; 1955 Mar; 33(5):85-93. PubMed ID: 14366210 [No Abstract] [Full Text] [Related]
3. Vasolastine in the treatment of arteriosclerosis. NOORDSIJ AJ; SMITH JA Am J Psychiatry; 1958 Mar; 114(9):836. PubMed ID: 13508908 [No Abstract] [Full Text] [Related]
4. [Treatment of atherosclerosis with vasolastine]. NOORDSIJ AJ; SMITH JA Ned Tijdschr Geneeskd; 1958 Oct; 102(42):2040-4. PubMed ID: 13613399 [No Abstract] [Full Text] [Related]
5. [The effects of vasolastine on experimental sclerosis in rats and arteriosclerosis in humans]. HOOGERWERF S Arztl Forsch; 1955 Nov; 9(11):I/540-6. PubMed ID: 13302006 [No Abstract] [Full Text] [Related]
6. Reserpine in the treatment of organic and senile psychosis. ABD-EL-NABY S J Egypt Med Assoc; 1957; 40(9):666-81. PubMed ID: 13525540 [No Abstract] [Full Text] [Related]
7. Psychiatric aspects of ageing. Mulligan JA Gerontol Clin (Basel); 1968; 10(3):139-45. PubMed ID: 5647001 [No Abstract] [Full Text] [Related]
8. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Montgomery EB Neurology; 2007 Jan; 68(1):81; author reply 81. PubMed ID: 16585044 [No Abstract] [Full Text] [Related]
9. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Aarsland D; Emre M; Lees A; Poewe W; Ballard C Neurology; 2007 Jan; 68(1):80; author reply 81. PubMed ID: 17200503 [No Abstract] [Full Text] [Related]
10. [Peyote alkaloids in the therapy of autonomic neurological conditions & especially in rheumatic heart disease & presenile states]. WAHL M Gaz Med Fr; 1958 Sep; 65(17):1397-9. PubMed ID: 13586559 [No Abstract] [Full Text] [Related]
11. [5 years of vasolastine therapy]. HOOGERWERF S Geneeskd Gids; 1960 Dec; 38():553-7. PubMed ID: 13715706 [No Abstract] [Full Text] [Related]
12. [Premature failure conditions]. Bronisch FW Wien Med Wochenschr; 1968 Feb; 118(5):83-6. PubMed ID: 5664024 [No Abstract] [Full Text] [Related]
13. [Clinical observations on citrogenase-aminoxidase-tyrosinase (Vasolastine)]. de Oliveira JM Hospital (Rio J); 1968 Sep; 74(3):751-4. PubMed ID: 5303759 [No Abstract] [Full Text] [Related]
14. Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Miyasaki JM; Shannon K; Voon V; Ravina B; Kleiner-Fisman G; Anderson K; Shulman LM; Gronseth G; Weiner WJ; Neurology; 2006 Apr; 66(7):996-1002. PubMed ID: 16606910 [TBL] [Abstract][Full Text] [Related]